New approaches to prevent intestinal toxicity of irinotecan-based regimens

Andrea Alimonti, Alain Gelibter, Ida Pavese, Francesco Satta, Francesco Cognetti, Gianluigi Ferretti, Debora Rasio, Aldo Vecchione, Mario Di Palma

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Background. Irinotecan is a selective inhibitor of topoisomerase I, an enzyme part of the replication and transcription system of DNA. Irinotecan is employed, with different modalities, in the treatment of metastatic colorectal cancer, and recently it has been officially approved in association with fluorouracil (FU) and leucovorin (LV) as a first-line option in metastatic colorectal cancer. Results. One of the problems linked to the administration of this drug is the high intestinal toxicity, which constitutes its dose limiting toxicity (DLT). In routine practice, loperamide is employed as symptomatic drug for the treatment of CPT-11-induced diarrhoea, but is not completely adequate to control the problem. The role of the intestinal bacterial microflora in the pathogenesis of CPT-11-induced intestinal toxicity has been recently discovered. The active metabolite of CPT-11, SN38, is generated from CPT-11 by sieric carboxylesterase, and subsequently conjugated to SN38-G by hepatic UDP-glucuronyltransferase. SN38-G is the inactive metabolite of CPT-11 and is excreted into the small intestine, from which it is eliminated in the faeces. Some studies have shown the ability of intestinal bacterial β-glucoronidases to transform SN38-G into SN38, causing direct damage to the intestinal mucosa. Thus, alternative strategies such as intestinal alkalinization and anti-cyclooxygenase 2 (COX-2) therapy have been explored. Conclusions. In this review, we will illustrate the mechanisms which cause the CPT-11-induced diarrhoea and the potential measures available to prevent it.

Original languageEnglish
Pages (from-to)555-562
Number of pages8
JournalCancer Treatment Reviews
Volume30
Issue number6
DOIs
Publication statusPublished - Oct 2004

Fingerprint

irinotecan
Colorectal Neoplasms
Diarrhea
Loperamide
Topoisomerase I Inhibitors
Glucuronosyltransferase
Carboxylesterase
Uridine Diphosphate
Leucovorin
Cyclooxygenase 2
Intestinal Mucosa

Keywords

  • Bacterial β-glucuronidase inhibitors
  • Diarrhoea
  • Irinotecan

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Alimonti, A., Gelibter, A., Pavese, I., Satta, F., Cognetti, F., Ferretti, G., ... Di Palma, M. (2004). New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treatment Reviews, 30(6), 555-562. https://doi.org/10.1016/j.ctrv.2004.05.002

New approaches to prevent intestinal toxicity of irinotecan-based regimens. / Alimonti, Andrea; Gelibter, Alain; Pavese, Ida; Satta, Francesco; Cognetti, Francesco; Ferretti, Gianluigi; Rasio, Debora; Vecchione, Aldo; Di Palma, Mario.

In: Cancer Treatment Reviews, Vol. 30, No. 6, 10.2004, p. 555-562.

Research output: Contribution to journalArticle

Alimonti, A, Gelibter, A, Pavese, I, Satta, F, Cognetti, F, Ferretti, G, Rasio, D, Vecchione, A & Di Palma, M 2004, 'New approaches to prevent intestinal toxicity of irinotecan-based regimens', Cancer Treatment Reviews, vol. 30, no. 6, pp. 555-562. https://doi.org/10.1016/j.ctrv.2004.05.002
Alimonti, Andrea ; Gelibter, Alain ; Pavese, Ida ; Satta, Francesco ; Cognetti, Francesco ; Ferretti, Gianluigi ; Rasio, Debora ; Vecchione, Aldo ; Di Palma, Mario. / New approaches to prevent intestinal toxicity of irinotecan-based regimens. In: Cancer Treatment Reviews. 2004 ; Vol. 30, No. 6. pp. 555-562.
@article{4b82871489f34096812ee377cf1272e9,
title = "New approaches to prevent intestinal toxicity of irinotecan-based regimens",
abstract = "Background. Irinotecan is a selective inhibitor of topoisomerase I, an enzyme part of the replication and transcription system of DNA. Irinotecan is employed, with different modalities, in the treatment of metastatic colorectal cancer, and recently it has been officially approved in association with fluorouracil (FU) and leucovorin (LV) as a first-line option in metastatic colorectal cancer. Results. One of the problems linked to the administration of this drug is the high intestinal toxicity, which constitutes its dose limiting toxicity (DLT). In routine practice, loperamide is employed as symptomatic drug for the treatment of CPT-11-induced diarrhoea, but is not completely adequate to control the problem. The role of the intestinal bacterial microflora in the pathogenesis of CPT-11-induced intestinal toxicity has been recently discovered. The active metabolite of CPT-11, SN38, is generated from CPT-11 by sieric carboxylesterase, and subsequently conjugated to SN38-G by hepatic UDP-glucuronyltransferase. SN38-G is the inactive metabolite of CPT-11 and is excreted into the small intestine, from which it is eliminated in the faeces. Some studies have shown the ability of intestinal bacterial β-glucoronidases to transform SN38-G into SN38, causing direct damage to the intestinal mucosa. Thus, alternative strategies such as intestinal alkalinization and anti-cyclooxygenase 2 (COX-2) therapy have been explored. Conclusions. In this review, we will illustrate the mechanisms which cause the CPT-11-induced diarrhoea and the potential measures available to prevent it.",
keywords = "Bacterial β-glucuronidase inhibitors, Diarrhoea, Irinotecan",
author = "Andrea Alimonti and Alain Gelibter and Ida Pavese and Francesco Satta and Francesco Cognetti and Gianluigi Ferretti and Debora Rasio and Aldo Vecchione and {Di Palma}, Mario",
year = "2004",
month = "10",
doi = "10.1016/j.ctrv.2004.05.002",
language = "English",
volume = "30",
pages = "555--562",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - New approaches to prevent intestinal toxicity of irinotecan-based regimens

AU - Alimonti, Andrea

AU - Gelibter, Alain

AU - Pavese, Ida

AU - Satta, Francesco

AU - Cognetti, Francesco

AU - Ferretti, Gianluigi

AU - Rasio, Debora

AU - Vecchione, Aldo

AU - Di Palma, Mario

PY - 2004/10

Y1 - 2004/10

N2 - Background. Irinotecan is a selective inhibitor of topoisomerase I, an enzyme part of the replication and transcription system of DNA. Irinotecan is employed, with different modalities, in the treatment of metastatic colorectal cancer, and recently it has been officially approved in association with fluorouracil (FU) and leucovorin (LV) as a first-line option in metastatic colorectal cancer. Results. One of the problems linked to the administration of this drug is the high intestinal toxicity, which constitutes its dose limiting toxicity (DLT). In routine practice, loperamide is employed as symptomatic drug for the treatment of CPT-11-induced diarrhoea, but is not completely adequate to control the problem. The role of the intestinal bacterial microflora in the pathogenesis of CPT-11-induced intestinal toxicity has been recently discovered. The active metabolite of CPT-11, SN38, is generated from CPT-11 by sieric carboxylesterase, and subsequently conjugated to SN38-G by hepatic UDP-glucuronyltransferase. SN38-G is the inactive metabolite of CPT-11 and is excreted into the small intestine, from which it is eliminated in the faeces. Some studies have shown the ability of intestinal bacterial β-glucoronidases to transform SN38-G into SN38, causing direct damage to the intestinal mucosa. Thus, alternative strategies such as intestinal alkalinization and anti-cyclooxygenase 2 (COX-2) therapy have been explored. Conclusions. In this review, we will illustrate the mechanisms which cause the CPT-11-induced diarrhoea and the potential measures available to prevent it.

AB - Background. Irinotecan is a selective inhibitor of topoisomerase I, an enzyme part of the replication and transcription system of DNA. Irinotecan is employed, with different modalities, in the treatment of metastatic colorectal cancer, and recently it has been officially approved in association with fluorouracil (FU) and leucovorin (LV) as a first-line option in metastatic colorectal cancer. Results. One of the problems linked to the administration of this drug is the high intestinal toxicity, which constitutes its dose limiting toxicity (DLT). In routine practice, loperamide is employed as symptomatic drug for the treatment of CPT-11-induced diarrhoea, but is not completely adequate to control the problem. The role of the intestinal bacterial microflora in the pathogenesis of CPT-11-induced intestinal toxicity has been recently discovered. The active metabolite of CPT-11, SN38, is generated from CPT-11 by sieric carboxylesterase, and subsequently conjugated to SN38-G by hepatic UDP-glucuronyltransferase. SN38-G is the inactive metabolite of CPT-11 and is excreted into the small intestine, from which it is eliminated in the faeces. Some studies have shown the ability of intestinal bacterial β-glucoronidases to transform SN38-G into SN38, causing direct damage to the intestinal mucosa. Thus, alternative strategies such as intestinal alkalinization and anti-cyclooxygenase 2 (COX-2) therapy have been explored. Conclusions. In this review, we will illustrate the mechanisms which cause the CPT-11-induced diarrhoea and the potential measures available to prevent it.

KW - Bacterial β-glucuronidase inhibitors

KW - Diarrhoea

KW - Irinotecan

UR - http://www.scopus.com/inward/record.url?scp=4444241175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444241175&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2004.05.002

DO - 10.1016/j.ctrv.2004.05.002

M3 - Article

C2 - 15325035

AN - SCOPUS:4444241175

VL - 30

SP - 555

EP - 562

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 6

ER -